Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Julia Driessen, Marie José Kersten*, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

Original languageEnglish
Pages (from-to)2853-2862
Number of pages10
JournalLeukemia
Volume36
Issue number12
Early online date14 Oct 2022
DOIs
Publication statusPublished - Dec 2022

Bibliographical note

Funding Information:
This work was supported by research funding from Takeda.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.

Fingerprint

Dive into the research topics of 'Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP'. Together they form a unique fingerprint.

Cite this